Ngwa ọgwụ ọhụrụ nyocha maka ịba ọcha n'anya B

Enwere ihe dị ka nde 1.59 ndị ọrịa ịba ọcha n'anya B (CHB) na-adịghị ala ala na US Ascletis Pharma Inc. mara ọkwa taa nkwado ngwa nyocha Ọhụrụ Drug (IND) nke US Food and Drug Administration (FDA) na mmalite nke mmepe zuru ụwa ọnụ nke ASC22 (Envafolimab) , nke mbụ na klaasị, nke subcutaneously na-enye PD-L1 mgbochi maka ọgwụgwọ ọrụ nke ịba ọcha n'anya B (CHB).

Print Friendly, PDF & Email

Akwụkwọ nyocha na nso nso a[1], akpọrọ “Mbawanye nke Ọrịa ịba ọcha n'anya B na-adịghị ala ala na United States” nke e bipụtara na June 2020, gosipụtara ọnụ ọgụgụ zuru oke maka ọrịa ịba ọcha n'anya B (HBV) na US nke ndị ọrịa nde 1.59 1.25-2.49 nde). Ma Òtù Ahụ Ike Ụwa (WHO) na Ngalaba Na-ahụ Maka Ahụ Ike na Ọrụ Ndị Mmadụ (DHHS) akọwapụtala atụmatụ mkpochapụ ịba ọcha n'anya.

Ọmụmụ ASC22 Phase IIb (ClinicalTrials.gov Identifier: NCT04465890) bụ usoro nyocha, otu-ìsì, ebe a na-achịkwa ebebo, nnwale ụlọ ọgwụ ọtụtụ etiti na China nke na-enyocha ịdị mma na nchekwa nke ndị ọrịa 149 CHB maka ọgwụgwọ izu 24 nke 1 mg / n'arọ ma ọ bụ 2.5 mg/kg ASC22 ma ọ bụ placebo dabara na-enye otu ugboro kwa izu abụọ (Q2W) yana njikọ NA. Nsonaazụ nwa oge, nke anabatara maka ngosipụta ọnụ na Oge nkwụsịtụ na Imeju Meeting® 2021 site na American Association for Study of Liver Diseases (AASLD) gosiri na n'ime ndị ọrịa nwere ọkwa nke ịba ọcha n'anya B elu antigen (HBsAg) ọkwa ≤ 500 IU. / ml, ihe dị ka 19% (3/16) nke ndị ọrịa nọ n'ime otu ọgwụgwọ ahụ nwetara mfu HBsAg na enweghị isiokwu enwetara HBsAg n'ime otu placebo yana enweghị nlọghachi mgbe usoro ikpeazụ nke ASC22 gasịrị, na-egosi ọgwụgwọ ọrụ HBV.

Usoro IIa na IIb ọmụmụ ụlọ ọgwụ nke ASC22 maka ọgwụgwọ ọrụ HBV ka ahọpụtara maka isonye na "Kachasị mma nke nchịkọta imeju imeju" na 2021 site na kọmitii nyocha AASLD. Nsonye dị otú ahụ bụ nsọpụrụ pụrụ iche ma na-egosi ọkwa dị elu nke kọmitii nyocha AASLD na-eleba anya n'ihe nyocha Ascletis na ọgwụgwọ ọrụ CHB.

Ascletis kwupụtara na ya enwetala akwụkwọ ikike zuru ụwa ọnụ na nke pụrụiche dị ka nke 8 November, 2021 site na Suzhou Alphamab ịzụlite na ịzụ ahịa ASC22 maka ọrịa nje niile gụnyere ịba ọcha n'anya B. Akwụkwọ Ascletis na-ere n'ụwa nile maka ASC22 nke ọrịa nje niile.

ASC22 bụ ọkwa immunotherapy kachasị elu n'ụwa maka ọgwụgwọ ọrụ CHB, ntụgharị HBsAg, site na igbochi ụzọ PD-1/PD-L1.

Print Friendly, PDF & Email

Akụkọ ndi ozo

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment

2 Comments

  • Nsonaazụ ịba ọcha n'anya B m tụgharịrị na-adịghị mma ka m jiri ọgwụ herbal Garden HBV mee ihe maka izu isii. M nwalere ikpeazụ 2021 ma ka na-adịghị mma. Ekele niile diri Ogige Herbal. Ị nwere ike ịkpọtụrụ ha site na herbalgarden4@gmail.com maka ọgwụgwọ ọrịa ọ bụla na-adịghị ala ala